The N-terminal regulatory region of the high affinity cAMP-specific phosphodiesterase, PDE7A1, contains two copies of the cAMPdependent kinase (PKA) pseudosubstrate site RRGAI. In ␤TC3 insulinoma cells, PDE7A1 co-localizes with PKA II in the Golgicentrosome region. The roles PDE7A1 and its regulatory region play in cAMP signaling were examined by studying interactions with PKA subunits. PDE7A1 associates with the dissociated C subunit of PKA (C), but does not bind tetrameric PKA holoenzyme. High affinity binding of C by PDE7A1 inhibits kinase activity in vitro (IC 50 ‫؍‬ 0.5 nM). The domain containing PKA pseudosubstrate sites at the N terminus of PDE7A1 mediates complex formation with C. The PDE7A1 N-terminal repeat region inhibits C activity in CHO-K1 cells and also suppresses C dependent, cAMP-independent, physiological responses in yeast. Thus, PDE7A1 possesses a non-catalytic activity that can contribute to the termination of cAMP signals via direct inhibition of C. This study identifies a novel inhibitor of PKA and a non-catalytic affect of a cyclic nucleotide phosphodiesterase.
The N-terminal regulatory region of the high affinity cAMP-specific phosphodiesterase, PDE7A1, contains two copies of the cAMPdependent kinase (PKA) pseudosubstrate site RRGAI. In ␤TC3 insulinoma cells, PDE7A1 co-localizes with PKA II in the Golgicentrosome region. The roles PDE7A1 and its regulatory region play in cAMP signaling were examined by studying interactions with PKA subunits. PDE7A1 associates with the dissociated C subunit of PKA (C), but does not bind tetrameric PKA holoenzyme. High affinity binding of C by PDE7A1 inhibits kinase activity in vitro (IC 50 ‫؍‬ 0.5 nM). The domain containing PKA pseudosubstrate sites at the N terminus of PDE7A1 mediates complex formation with C. The PDE7A1 N-terminal repeat region inhibits C activity in CHO-K1 cells and also suppresses C dependent, cAMP-independent, physiological responses in yeast. Thus, PDE7A1 possesses a non-catalytic activity that can contribute to the termination of cAMP signals via direct inhibition of C. This study identifies a novel inhibitor of PKA and a non-catalytic affect of a cyclic nucleotide phosphodiesterase.
Cyclic AMP (cAMP) is a second messenger that mediates diverse cellular responses to hormones and neurotransmitters. Cyclic AMP levels are regulated by rates of adenylyl cyclase-catalyzed synthesis and phosphodiesterase (PDE) 2 -mediated hydrolysis. Several targets for cAMP are known: cAMP-dependent protein kinases (PKAs), cAMP-activated guanine nucleotide exchange factors, and ion channels (1) (2) (3) (4) . PKAs phosphorylate multiple substrates and thereby regulate a broad range of physiological processes including gene expression via CREB/ATF and co-stimulatory transcription factors, glycogenolysis, lipolysis, catecholamine biosynthesis, synaptic transmission, and ion channel/transporter activities (1, 2, (5) (6) (7) . PKA activity is stimulated by binding of cAMP to the regulatory subunits of inactive, tetrameric PKA complexes, and the consequent dissociation of active catalytic subunits. Free catalytic subunit (C) phosphorylates PKA substrates including nuclear targets. During interphase, the vast majority of PKA regulatory subunits and tetrameric complexes are excluded from the nucleus. A substantial proportion (principally PKA II) can be tethered to specific subcellular sites via interactions with anchor proteins (8) . Subcellular targeting of PKA is often required for efficient transduction of cAMP signals (9) . Down-regulation of PKA activity is achieved via PDE-mediated degradation of cAMP, dissociation of ligands from receptors, receptor desensitization, inhibitory G proteins, GTPase-activating proteins, holoenzyme reassociation, C degradation, compensatory expression of PKA regulatory subunit, and direct inhibition by the PKA inhibitor, PKI (10 -15) . In addition to directly inhibiting catalytic activity, PKI also promotes export of C from the nucleus (16 -18) .
PKA regulatory subunits and PKI bind to C with high affinity (1, 2) . The hinge regions of the type I and type II regulatory subunits of PKA interact with the catalytic cleft of C via their PKA pseudosubstrate and substrate sites, respectively (19 -22) . Mutations within C recognition sites in the hinge region of the regulatory subunits can generate an active, cAMP-independent, mutant holoenzyme (23) . PKI inhibits C via binding of a PKA pseudosubstrate site to the catalytic cleft of C (21, 24) .
A multitude of cyclic nucleotide PDEs hydrolyze cAMP in mammalian cells. Cyclic nucleotide PDEs are classified into eleven families based on their amino acid sequence, sensitivity to cofactors and inhibitory drugs and substrate specificity and affinity (25, 26) . PDEs have similar C-terminal catalytic domains and divergent N-terminal regulatory domains that contain cofactor or cGMP binding sites, targeting, and other regulatory sequences. Both cell type-specific gene expression and variable mRNA splicing further diversify the isozyme composition of the cyclic nucleotide PDE superfamily in mammals.
PDE7A is a high affinity cAMP-specific PDE that we isolated by functional complementation of phosphodiesterase deficient yeast (27) . Within the regulatory domain of the PDE7A1 splice variant, a motif that contains a PKA pseudosubstrate site is tandemly repeated. The presence of PKA pseudosubstrate sites in PDE7A1 N terminus raises the possibility that, like PKI and PKA regulatory subunits, PDE7A1 can limit cAMP signaling by binding and inhibiting C. This study documents direct inhibitory interactions between PDE7A1 and PKA.
EXPERIMENTAL PROCEDURES
Cell Culture, Yeast Strains, Growth Conditions, Transformation, and Assays-␤TC3 cells were cultured as described and early passages (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) were maintained (28) . Yeast-rich medium contains 1% Bacto-yeast extract, 2% Bacto-peptone, and 2% dextrose. Synthetic dropout media was prepared as described (29 (29) . Interactions in the two hybrid system, and heat shock assays were performed as described (30) .
Plasmids and Plasmid Construction-Standard procedures were used for bacterial transformation, plasmid DNA preparation, and plasmid construction (29) . The LexA-PDE7A1 bait, PD7-M1, was constructed by fusing the PDE7A1 ORF as a SalI fragment (from L22M1, Ref. 27) in-frame to the LexA C terminus via the SalI site of pBTM117 (30) . PDE7A1 N-terminal deletions were generated by polymerase chain reaction (PCR) amplification with Pfu polymerase (Stratagene) using the TM22 template and a common C-terminal oligonucleotide M15-3xho 5Ј-GCGTACTCGAGGGTCA-TGATAACCGAT. The 5Ј oligonucleotides used were: PDE7-repeat2, 5Ј-GTACGTCGACACCCAATCCCCGGCAGCTCTCTCA for PD-PS1; HSM7-RRxho, 5Ј-CGATCTCGAGTATGAGGCGTGGAGCTATTTC-CTATG for PD-PS2; L22M2 and L22M3 for PD-M2 and PD-M3, respectively (27) . PCR products were digested with the restriction enzymes XhoI or SalI and XhoI and cloned into the pBMT117 SalI site. The fusion of the GAL4 transcription activation domain to the catalytic subunit of PKA was generated by inserting the NcoI-EcoRV fragment containing the murine C ORF downstream to the NcoI-EcoRV sites of pACT2. Recombinant His-tagged PDE7A1 fusion proteins were expressed from the bacterial pET-14b expression plasmid (Novagen). Full-length PDE7A1 and the M2 deletion were generated as detailed above for LexA fusions and were cloned into the XhoI site of a modified pET-14b plasmid. The PD7-N-ter construct expressing PDE7A1 residues 1-57 was generated by blunting and deleting the BclI-EspI fragment from the His tag full-length PDE7A1 expression plasmid. The pGAL-GST-PDE7A1 yeast expression plasmid for galactose driven production of GST fusions to full-length PDE7A1 was generated by subcloning the PDE7A1 ORF into the SalI-SmaI sites of pEGKT-Ura
Preparation of Cell Extracts-␤TC3 cells were washed twice with ice-cold phosphate-buffered-saline (PBS) and homogenized in protein extraction buffer containing 50 mM Tris, pH 7.5, 250 mM sucrose, 1 mM DTT, 10 mM EDTA, 1 mM EGTA, 5 mM MgCl 2 , and the protease inhibitors aprotinin (5 g/ml), leupeptin (5 g/ml), pepstatin (5 g/ml), soybean trypsin inhibitor (50 g/ml), 1 mM phenylmethylsulfonyl fluoride, and 10 mM benzamidine. Soluble cell fractions were obtained after a 150,000 ϫ g centrifugation at 4°C for 30 min.
Antisera Production, Purification, and Immunoprecipitations-Rabbit polyclonal anti-PDE7A1 antibodies were generated and affinity-purified as described (32) . Chicken polyclonal anti-PDE7A1 antibodies were raised against a recombinant mouse PDE7A1 C-terminal peptide spanning residues 237-456 of PDE7A1 (33) . Antibodies were extracted from chicken egg yolks by polyethylene glycol precipitation and were affinity-purified on an antigen-coupled cyanogen bromide-activated Sepharose 4B column.
Affinity-purified chicken antibodies were coupled to activated immunoaffinity support Affi-Gel 10. 100 g of soluble ␤TC3 cell extracts were immunoprecipitated with immobilized anti-PDE7A1 chicken antibodycoupled beads for 3 h at 4°C with mild rotation. Immune complexes were washed five times with 250 mM NaCl, 50 mM Tris, pH 7.5. Immunoprecipitated proteins were released from the beads by boiling in sample buffer and analyzed by SDS-PAGE and immunodetection on Western blots with affinity-purified rabbit anti-PDE7A antibodies (1:500), rabbit anti-C antibodies (1:1000), and rabbit anti-PKA RII␣ antibodies (1:1000).
Indirect Immunofluorescence-Cells were grown on poly-L-lysinecoated glass coverslips for 2-3 days, fixed in 3.7% formaldehyde for 10 min, and permeabilized with 0.25% Nonidet P-40 for 15 min. After several PBS washes, slides were blocked with 3% bovine serum albumin for 1 h, and then incubated with primary antibody for 1.5 h in blocking buffer with the following antibodies: rabbit anti-PDE7A1 (1:50), anti-RII␣ monoclonal antibodies (1:25, Transduction Laboratories), anti-␤-COP monoclonal antibodies (1:200, Stressgen), anti-␥-tubulin monoclonal antibodies (1:300, Sigma). After washes with 0.2% Nonidet P-40/ PBS, cells were incubated with appropriate secondary antibody conjugated to fluorescent dyes at a dilution of 1:100 for 1 h. Slides were mounted with DABCO anti-fade mounting medium and visualized by fluorescence confocal microscopy.
Expression, Purification, and Folding of Bacterial Histidine-tagged Proteins-Expression plasmids for His-tagged full-length PDE7A1, and the M2 and N-ter deletions, were transformed into BL21 (DE3) bacterial cells. Expression was induced with 0.4 mM IPTG for 3 h at 37°C. Histagged full-length PDE7A1, M2 and N-ter proteins were found in inclusion bodies of cell extracts after two rounds of 900 psi pressure (French press) and followed by three rounds of 1 min of sonication pulse with a 3-min interval in extraction buffer containing 0.1 M Tris, pH 8 and 1 mM EDTA. Pellets were separated by centrifugation at 39,000 ϫ g for 20 min and solubilized in 6.75 M guanidine hydrochloride, 0.1 M Tris, pH 8. The supernatant after a 15 min, 10,000 ϫ g spin, and 0.45-m filtration, was incubated with pre-equilibrated Ni 2ϩ -NTA-charged beads at 4°C for 30 min with gentle rocking in binding buffer containing 6.75 M guanidine hydrochloride, 0.1 M Tris, pH 8, 0.5 M Nacl, 18 mM ␤-mercaptoethanol, 10 mM imidazole. The beads were washed with 10-bed volumes of binding buffer, 5-bed volumes of wash buffer (binding buffer with 25 mM imidazole), 5-bed volumes of wash buffer II (binding buffer with 50 mM imidazole), and 5-bed volumes of elution buffer (binding buffer with 100 mM imidazole). Renaturation of the purified His-PDE7A1 proteins was carried out in 50 mM Tris, pH 8.5, 1 M arginine⅐HCl, 50% ethylene glycol, 0.2 M MgCl 2 and 5 mM DTT at 0.4 g/ml at 10°C for 16 h as described by Richter et al. (34) . Following dialysis against 50 mM Tris, pH 7.5, 20% ethylene glycol, and 2 mM DTT, renatured proteins were quantified following SDS-PAGE and silver staining. His-PDE7A1 proteins with specific activity ranging from 9.6 to 43.375 pmol/min/g were picked for further analysis.
Expression and Purification of GST-PDE7A1 from Yeast-The GST-PDE7A1 expression plasmid was transformed into RS334 cells, and transformants were grown exponentially in synthetic medium lacking uracil. GST-PDE7A1 expression was induced with 4% galactose for 6 h. Protein extracts were prepared with glass beads in PBS buffer containing 0.5% Triton X-100 and centrifuged at 10,000 ϫ g for 15 min. The supernatant was subjected to glutathione-Sepharose purification as recommended by Amersham Biosciences.
PKA Activity Assays and PDE7A1 Phosphorylation-Recombinant C (Cell Signaling) was assayed for phosphotransferase activity using the synthetic peptide kemptide (Sigma) as a substrate. 25-l reactions contained 50 mM MOPS, pH 7, 10 mM MgCl 2 , 200 M ATP, 250 g/ml bovine serum albumin, 200 M kemptide, 6000 Ci/mmol of [␥-32 P]ATP, and 0.1 ng of C. Increasing amounts of purified full-length PDE7A1, the deletions M2 and N-ter, PKI (native protein, Calbiochem), or no protein, in a fixed volume of dilution buffer were added to the reactions. Reactions were incubated for 15 min at 37°C, chilled on ice, and then dotted onto Whatman P-81 ion exchange paper. Paper discs were washed three times in 75 mM phosphoric acid, once with 95% ethanol, dried, and subjected to liquid scintillation counting.
In vitro phosphorylation of His-PDE7A1 or GST-PDE7A1, was carried out with recombinant C that was purified from Escherichia coli and lacked contaminating PDE activities (Calbiochem). Renatured His-PDE7A1 and M2 proteins (1.2 and 1 ng, respectively), and purified RII␣ (1 ng) were incubated with 1 ng of C subunit in 50 l of 50 mM Tris, pH 7.5, 10 mM MgCl 2 , 200 M ATP, and 1.2 Ci of [␥-
32 P]ATP for 30 min at 37°C. Phosphoproteins were detected by SDS-PAGE and autoradiography. GST-PDE7A1 purified from yeast was incubated with 125 ng of C in the buffer indicated above. After a 15-min incubation period at 30°C with continuous mild shaking for GST-PDE7A1 beads, proteins were boiled in SDS sample buffer. To measure PDE activity, kinase reaction was carried out in the absence of [␥-
32 P]ATP. PDE assays were performed after the beads were washed three times in a buffer containing 40 mM Tris, pH 7.5, 10 mM MgCl 2 at 4°C. 3 H]cAMP. Reactions were carried out for 15 min at 30°C and terminated by addition of 10 mM EDTA, 1.25 mM of AMP, and of cAMP. Adenosine and cAMP were separated by anion exchange chromatography (AG-1-X8, Bio-Rad). Adenosine was eluted with 4 ml of 50% ethanol and the 3 H content of the eluate was determined. Expression and PKA Activity in CHO-K1 Cells-CHO-K1 cells were transfected with a plasmid expressing a heterodimeric ecdysone receptor (pVgRXR, Invitrogen). PDE7A1-derived deletion mutants were cloned into the expression vector pIND(SP1) and electroporated into CHO-VgRXR cells. Expression of PDE7A1-derived proteins was induced with 10 M Pronasterone A for 24 h, and the cells were then removed from the culture plates with 0.5 mM EDTA, and washed with 10 mM Tris, pH 7.5, and 250 mM sucrose. Cells were then stimulated with 10 M forskolin for 10 min, extracted, and subjected to kinase assays using kemptide as a substrate in the absence and presence of 100 nM PKI and in the absence and presence of 10 M cAMP. Co-electroporation with EGFP expression vector demonstrated transduction efficiencies higher than 95%.
RESULTS
Association of PDE7A1 with the Catalytic Subunit of PKA-Two repeated sequences, eighteen amino acids each, within the PDE7A1 N terminus contain PKA pseudosubstrate sites (RRGAI) where alanine replaces the phosphorylatable serine/threonine residue of the RRXSF PKA consensus phosphorylation site (Fig. 1) . To determine whether these pseudosubstrate sites, or other domains within the PDE7A1 sequence, promote interaction with C, we investigated possible associations between PDE7A1 and PKA by co-immunoprecipitation assays. C, but not the type II regulatory subunits of PKA (RII), was observed in anti-PDE7A1 immunoprecipitates from ␤TC3 cell extracts (Fig. 2) . RI regulatory subunits of PKA were also excluded from immune complexes isolated with anti-PDE7A1 antibodies (not shown). PDE7A1 and C were isolated specifically by anti-PDE7A1 antibodies and not with preimmune immunoglobulins. An identical co-immunoprecipitation pattern was observed when cells were lysed in 10-fold larger volume, indicating that the association between PDE7A1, and C is not likely to occur during, or after, extraction. Typically, 40% of the cellular PDE7A1 and 2% of C were bound by anti-PDE7A1 antibodies. Thus, correcting for recovery, it appears that about 5% of cellular C associates with PDE7A1 in unstimulated cells. The fraction of cellular C associated with PDE7A1 did not increase upon hormonal stimulation with glucagon like peptide 1 or upon adenylyl cyclase activation with forskolin.
Co-localization of PDE7A1 and PKA II-To assess the proximity of PDE7A1 to PKA in unstimulated cells we examined the subcellular localization of PDE7A1 and PKA in ␤TC3 insulinoma cells. Both FIGURE 2. Co-immunoprecipitation of PDE7A1 with C. 100 g of soluble ␤TC3 protein extract were immunoprecipitated with either preimmune immunoglobulins (Pre) or with affinity-purified chicken anti-PDE7A1 antibodies (IP). 10 g of cell extract (Ex) and immune complexes were resolved by SDS-PAGE and transferred to a polyvinylidene difluoride membrane. Immunodetection of PDE7A, C, and PKA RII was carried out with rabbit polyclonal antibodies directed against these proteins. PDE7A1 and PKA RII␣ regulatory subunits co-localized with the Golgi apparatus and centrosomes (Fig. 3) . Co-immunofluorescence and confocal microscopy of PDE7A1 and RII demonstrated their co-localization in an area adjacent to the nucleus that includes an intensely fluorescent spot (Fig. 3, panels A and B) . Diffuse background staining throughout the cytoplasm was indistinguishable from staining observed with purified rabbit preimmune immunoglobulins (Fig. 3, panel H) . Co-staining with antibodies to the Golgi-associated coatmer protein, ␤-COP, demonstrated that PDE7A1 associates with the outer face of Golgi membranes (Fig. 3, panels C and D) . PDE7A1 also co-localized with ␥-tubulin at the centrosome, an intensely labeled spot adjacent to the nucleus and within the Golgi area (Fig. 3, panels E and F) . Association of PDE7A1 with the outer face of the Golgi apparatus was disrupted upon treatment with nocodazole (Fig. 3, panel G) , suggesting that PDE7A1 localization to the Golgi may be mediated via interactions with microtubules or with microtubule-associated proteins. Consistent with the resistance of ␥-tubulin and the centrosome to nocodazole, the distribution of PDE7A1 to the centrosome was not affected by nocodazole and thus appears to be mediated by interactions that differ from those localizing PDE7A1 to the Golgi area. These observations demonstrate the coordinated subcellular localization of PDE7A1 and PKA II to the Golgi-centrosome perinuclear area.
In accordance with disruption of microtubule structures upon cold isotonic extraction, a high proportion of the PDE7A1 and RII proteins were found in the cytosol. PDE7A1 and RII associated with particulate fractions were resistant to extraction with salt and a non-ionic detergent and may represent a subpopulation tightly associated with anchor proteins in these cell fractions (not shown). Association of PDE7A1 and RII proteins with the outer face of the Golgi appear to be mediated via protein-protein interactions that are disrupted during extraction. Coimmunoprecipitation of PDE7A1 and C; however, demonstrates that at least some of the interactions between the two proteins are preserved in ␤TC3 cell extracts.
PDE7A1 N-terminal Repeats Are Required for Interaction with C-To confirm the interaction between PDE7A1 and C and map domain(s) required for association, we utilized the yeast two hybrid interaction detection system. The interaction of a bait consisting of a fusion of the LexA DNA binding domain to PDE7A1 with a fusion of the GAL4 transcription activation domain to C was detected by growth on histidine selection plates (Fig. 4) . Analysis of several PDE7A1 N-terminal deletions demonstrated that the N-terminal repeats of PDE7A1 are required for its interaction with C. A single repeat, RP2, was sufficient for interaction with C, but truncations that removed sequences upstream from the RRGAI pseudosubstrate site within RP2 abolished this interaction. These results were confirmed by ␤-galactosidase activity assays (not shown). Thus, in the yeast two hybrid system, the interaction between PDE7A1 and C requires repeats containing PKA pseudosubstrate sites. A single, intact repeat is sufficient for interaction between PDE7A1 and C. A single PKA pseudosubstrate site; however, cannot mediate this interaction indicating that amino acids located upstream of the pseudosubstrate site are critical for binding of PDE7A1 with C.
PDE7A1 Inhibits C kinase Activity in Vitro-Effects of PDE7A1 on C kinase activity were assessed in vitro. Full-length PDE7A1 (7A1), a truncation removing the two N-terminal repeats (M2, residues 65-482), and a peptide encompassing only the two repeats (Nter, residues 1-57), were fused to a histidine tag and expressed in E. coli. Because of persistent difficulties in expression and purification of soluble, full-length, active PDE7A1 proteins, recombinant proteins were recovered from insoluble inclusion bodies, affinity-purified by nickel-chelate chromatography and renatured into an active state. The biochemical properties of renatured PDE7A catalytic activity are comparable to those of endogenously expressed PDE7A1 and recombinant PDE7A catalytic activity derived from different cell types (27, 34 -36) . Purified proteins of the anticipated molecular weight were evident after SDS-PAGE and Coomassie Blue staining (Fig. 5, A and B) . After renaturation, fractions containing cAMP PDE of high specific activity were used in C kinase activity assays (Ͼ9.5 pmol/min/g protein). In vitro kinase assays performed with recombinant C revealed a dose-dependent inhibition of C by fulllength PDE7A1 or the N-ter peptide (Fig. 5C ). The M2 truncation that lacked the two N-terminal repeats failed to inhibit C. Thus, it appears that PDE7A1 inhibits C activity via an N-terminal domain that includes pseudosubstrate repeats. Full-length PDE7A1 inhibited C activity with an IC 50 value of 0.5 nM. Perhaps because of structural loss, the IC 50 value for the inhibition of C by the small PDE7A1 N-ter peptide was higher (1 nM). These results demonstrate high affinity binding of PDE7A1 with C via PDE7A1 pseudosubstrate repeats and the suppression of C kinase activity in vitro.
PDE7A1 Activity Is Not Modulated by C-To examine effects of C on PDE7A1 activity, partially purified active GST-PDE7A1 fusion protein was prepared. PDE activity of the GST-PDE7A1 fusion was unaffected by the presence of C, even at 1000-fold molar excess of C (Fig. 6) . Because phosphorylation by PKA can modulate PDE activity, it was important to determine whether PDE7A1 is phosphorylated on serine 84 within the putative PKA phosphorylation site found in its N terminus in vitro. Phosphorylation of full-length PDE7A1 was not detected either with GST-PDE7A1 or with the bacterially produced His tag PDE7A1 substrates even when a 50 -100-fold molar excess of C was used to (1), and of fusions of PDE7A1 deletions (2) (3) (4) (5) to LexA, with a fusion of C to the GAL4 activation domain are scored as ϩ or Ϫ in A. Growth on selective plates lacking histidine is depicted in B. Two repeats (RP1 and RP2) containing PKA pseudosubstrate sites, a consensus PKA phosphorylation site (P), and the catalytic domain (CAT ) of PDE7A1 are delineated. PDE7A1 and the domains fused to LexA as detailed in A are: full-length PDE7A1 (1), N-terminal truncation of residues 1-38 that removes the first pseudosubstrate repeat (2) , N-terminal truncation of residues 1-46 that removes the first pseudosubstrate repeat and sequences upstream of the second pseudosubstrate site (3), N-terminal truncation of residues 1-64 that removes the two pseudosubstrate repeats (4) , and N-terminal truncation of residues 1-146 that removes the entire regulatory regions (5, PD7-M3). Positive control (6) , interaction between S. cerevisiae CDC25 and H-ras. Negative control (7) , interaction between LexA and C.
overcome pseudosubstrate repeat-mediated inhibition (not shown). Although an established PKA substrate, RII␣, was phosphorylated efficiently in this assay, no phosphorylation of equimolar amount of fulllength PDE7A1 was detected, and only 2% of the equimolar amounts of the PDE7A1 M2 deletion mutant protein could be phosphorylated. As PDE7A1 appears to be a poor PKA substrate, these observations suggest that PKA does not regulate PDE7A1 activity either via its interactions with the PDE7A1 N terminus or via phosphorylation of PDE7A1.
PDE7A1 Inhibits C Kinase Activity in Vivo-To assess whether PDE7A1 can inhibit PKA-mediated signaling via pseudosubstrate sitemediated inhibition of C in vivo, we examined the effects of PDE7A1 on C kinase activity in CHO-K1 cells. For this purpose, an inducible system for co-expression of a heterodimeric ecdysone receptor and of PDE7A1 from a minimal heat shock promoter with modified ecdysone response elements upstream of it was established. Following pronasterone A-induced expression, cAMP synthesis was stimulated with forskolin and cell extracts were subjected to in vitro C kinase activity assays in the presence and absence of PKI. PKA specific activity was determined by deducting PKI-resistant activities from the total kinase activities measured with the PKA substrate kemptide (Fig. 7) . PKA activity detected in cells bearing a control plasmid was inhibited upon expression of fulllength PDE7A1 and of a short peptide bearing the two pseudosubstrate site repeats (Nter), but not upon expression of the M2 deletion mutant, which lacks the pseudosubstrate site repeats but retains PDE activity. Interestingly, PKA activity was stimulated further by in vitro addition of cAMP to extracts of control cells and of cells expressing M2, but not of cells expressing either full-length PDE7A1 or the Nter peptide. These observations demonstrate that PDE7A1 N-terminal sequences containing PKA pseudosubstrate sites inhibit C activity both in vivo and in vitro. In this experimental system, PDE7A1 inhibits PKA signaling strongly via its N terminus regulatory domain and only modestly via cAMP hydrolysis. It thus appears that PDE7A1 Nter residues constitute a powerful inhibitor of PKA C in vivo. FIGURE 5 . Inhibition of C by the PDE7A1 regulatory domain in vitro. Recombinant PDE7A1 and PDE7A1 domains were purified and renatured to an active state as detailed under "Experimental Procedures." A, purified full-length his-PDE7A1 (7A1) and His-N-terminal truncation of residues 1-64 that removes the two pseudosubstrate repeats (M2) fractionated by 12.5% SDS-PAGE. B, purified His-N-terminal fragment encompassing the two pseudosubstrate repeats (amino acids 1-57, Nter) fractionated by 20% SDS-PAGE. C, PKA kinase activity was determined using 0.1 ng of purified PKA C in the presence of increasing amounts of full-length PDE7A1 (7A1, circles) , of the M2 deletion mutant lacking residues 1-64 that removes the two pseudosubstrate repeats (squares), of the Nter PDE7A1 fragment containing the two pseudosubstrate repeats (half-filled squares), and of PKI (PKI, x) . Percentages of the remaining PKA kinase activity in the presence of the added proteins are plotted. Each curve represents the average of three independent assays with variation of less than 10% between assays. FIGURE 6. Effects of C on PDE7A1 activity. Activity ratios of purified GST-PDE7A1 in the presence of different amount of C to its activity in the absence of C are depicted. Cyclic AMP PDE assays were performed as described under "Experimental Procedures." C molar excess ranged from 200 -1000-fold. The plot represents the average of two independent assays, performed in duplicate, with variation of less than 10% between assays. FIGURE 7. Inhibition of C by the PDE7A1 regulatory domain in vivo. Plasmids encoding full-length PDE7A1 (PDE7A1), the N-ter PDE7A1 fragment containing the two pseudosubstrate repeats (Nter), the M2 PDE7A1 deletion mutant lacking residues 1-64 that removes the two pseudosubstrate repeats (M2), or control plasmid lacking an insert (Ϫ) were electroporated into CHO-K1 cells expressing a heterodimeric ecdysone receptor. Expression of PDE7A1-derived proteins was induced with 10 M Pronasterone A for 24 h, and the cells were then stimulated with 10 M forskolin for 10 min, extracted, and subjected to kinase assays using kemptide as a substrate in the absence (empty) and presence (gray fill) of 10 M cAMP and in the absence and presence of 100 nM PKI. Nonspecific background PKI-resistant PKA activity was subtracted from the total kinase activities measured in this assay (62) . Average of three independent experiments is presented with standard deviations. Electroporation efficiencies were Ͼ95%.
Cyclic AMP-independent Suppression of Yeast C Phenotypes by PDE7A1-To further assess whether PDE7A1 can inhibit C signaling in vivo via pseudosubstrate site-mediated interaction, we examined the effects of PDE7A1 on C-dependent phenotypes in yeast that are independent of cAMP levels. Constitutive activation of PKA in yeast resulting from the targeted disruption of the gene encoding the regulatory subunit of PKA, BCY1, elicits multiple defects including sensitivity to thermal stress during stationary phase (37) . The strain, PrC, lacks BCY1 and contains a single attenuated gene encoding the PKA catalytic subunit TPK1 (38, 39) . PrC cells serve as sensitive detectors for inhibition of PKA catalytic activity in the absence of regulatory subunits. Because mammalian C is a functional homolog of yeast C (40) , and since PDE7A1 interacts with the TPK1 catalytic subunit in a yeast two hybrid assay (not shown), changes in the phenotypes of PrC cells enables evaluation of effects of PDE7A1 on C.
PrC cells overexpressing the yeast PKA regulatory subunit BCY1 were resistant to heat shock at 55°C during stationary phase, whereas PrC cells overexpressing the yeast high affinity PDE, PDE2, were sensitive to heat shock, as were cells bearing the LEU2 marker plasmid (Fig.  8) . Thus, in accordance with their genotype, PrC cells were refractory to increased cAMP hydrolysis upon overexpression of a PDE, but were sensitive to direct inhibition of C by BCY1. Similarly, the heat sensitivity of PrC cells was suppressed by overexpression of full-length PDE7A1 bearing the two pseudosubstrate site repeats (PDE7A1), but not by PDE7A1 deletions that retained PDE activity but not the pseudosubstrate site repeats (PDE7-M2 and PDE7-M3). Conversely, a PDE7A1 deletion mutant retaining the two pseudosubstrate repeats and lacking catalytic activity blocked the heat sensitivity of PrC cells (not shown). These observations indicate that PDE7A1 can inhibit C phenotypes in vivo, most likely via direct inhibition of C activity.
DISCUSSION
We identified a non-catalytic activity of PDE7A1 that can contribute to the termination of cAMP signals. In ␤TC3 insulinoma cells, PDE7A1 co-localizes with PKA II but does not bind tetrameric PKA complexes. In these cells, PDE7A1 is associated with a small fraction of cellular C (ϳ5%). A high affinity interaction between PDE7A1 and C inhibits PKA kinase activity in vitro (IC 50 ϭ 0.5 nM). This interaction is mediated by PKA-pseudosubstrate sites within two repeated sequences at the PDE7A1 N terminus. PDE7A1 N-terminal repeat region inhibits C activity in CHO-K1 cells and suppresses C-dependent, cAMP-independent, physiological responses in yeast. These observations demonstrate that PDE7A1 can inhibit cAMP signaling via direct binding to C. Thus, this study identifies a novel inhibitor of PKA and a non-catalytic affect of a cyclic nucleotide PDE.
Like PKA regulatory subunits and PKI, PDE7A1 interacts with C and inhibits its kinase activity. Binding of C to the regulatory RI and RII subunits is mediated via R subunit pseudosubstrate/substrate sites and distinct domains located C-terminal to these sites (1, 2, 22, 41, 42) . Although the binding of RI and RII with C involves contacts with multiple residues, their inhibition of C is governed principally by the pseudosubstrate/substrate sites. Binding of PKI to C is mediated by its pseudosubstrate site and eleven critical residues located upstream of this site (7, 21, 24, 43) . The binding of C to PDE7A1 resembles its association with PKI in its high affinity and its requirement for interaction with amino acids preceding the pseudosubstrate site. Sequences N-terminal to the pseudosubstrate sites of PKI and PDE7A1, however, are not related. In particular, PDE7A1 lacks an arginine at position Ϫ6 and a phenylalanine at position Ϫ11 relative to the alanine residue in the pseudosubstrate site, which are critical for the high affinity binding of PKI to C. Evidently, the high affinity binding of PDE7A1 pseudosubstrate site sequences to the catalytic cleft of C involves interactions with amino acids other than those used by known PKA inhibitors.
Through an interaction with C, PDE7A1 inhibits PKA both in vitro and in vivo, and suppresses physiological effects of C in yeast cells. Thus, in addition to hydrolyzing cAMP, PDE7A1 can inhibit cAMP signaling via direct interaction with the catalytic subunit of PKA. Consequently, PDE7A1 can play a dual role in promoting PKA holoenzyme re-association following hormonal stimulation-localization of C to the vicinity of R/cAMP dimers and elimination of cAMP as it is released from R. R dimers compete effectively for binding with C pre-bound to PKI, and potentially also with C pre-bound to PDE7A1 (44) . The binding of C to R/cAMP dimers facilitates cAMP dissociation, a rate-limiting step in PKA re-association (45) (46) (47) . Cyclic AMP release from R is inhibited by physiological concentrations of cAMP (1 M), and rapid cAMP hydrolysis upon its release facilitates the release of the additional three cAMP molecules bound to R/cAMP and the consequent re-association of PKA. By virtue of its co-localization with RII and its hydrolytic activity, PDE7A1 is poised to facilitate the ordered release of cAMP from RII/ cAMP complexes. By virtue of its co-localization with PKA II and its ability to bind to C, PDE7A1 is also poised to limit C diffusion and to promote PKA re-association.
A small fraction of cellular C complexes with PDE7A1 in unstimulated cells, suggesting that PDE7A1 can regulate basal PKA II activity. In pancreatic ␤-cells, basal PKA activity is required to maintain a glucose competent state, thus permitting physiological glucose induced insulin secretion (48) . It is possible that under basal conditions, basal activity of PKA I is required to maintain responsiveness to glucose. Co-localization with PDE7A1 is a mechanism enabling selective inhibition of PKA II. It is possible that a decrease in the affinity of PDE7A1 for C that occurs upon its binding to cAMP may account, in part, for the absence of hormonally stimulated increase in the fraction of C associated with PDE7A1. In vitro, the binding of PDE7A1 to C is disrupted in the presence of 20 M cAMP, but not by lower cAMP concentrations (not shown). Thus, direct inhibitory effects of cAMP on PDE7A1⅐C complex formation are evident at cAMP concentrations relevant to hormonal stimulation, and suggest that factors other than cAMP may inhibit PDE7A1⅐C complex formation at cAMP concentrations lower than 20 M. Association with, and inhibition of, C by PDE7A1 may therefore be effective under physiological conditions where regulation of basal PKA activity is critical for cell function.
In mice, ablation of PDE7A catalytic activity did not affect T lymphocytes proliferation as anticipated from increases in cAMP content of these cells perhaps due to the expression of the PDE7A1 regulatory domain (49) . The targeted disruption of the PDE7A locus of these Ϫ tpk3 Ϫ ) were transformed with the control plasmid YEp13 (LEU2), and with plasmids expressing the yeast PDE2 phosphodiesterase (yPDE2), the yeast PKA regulatory subunit (BCY1), full-length PDE7A1 (PDE7-FL), the PDE7A1 M2 truncation lacking the two pseudosubstrate repeats (PDE7 M2, residues 65-482), and PDE7A1 M3 truncation lacking the entire regulatory region (PDE7 M3, residues 147-482). Four transformants were patched onto synthetic media lacking leucine, incubated at 30°C for 2 days, and then replica plated to an untreated plate (Ϫ) and to a plate that was subjected to a 55°C heat shock treatment for 10 min (55°C, 10 min). Plates were photographed after a recovery period of 1 day at 30°C.
PDE7A deficient mice can express the PDE7A regulatory domain as well as the internal ribosome entry site and the colorimetric marker inserted downstream of it. Accordingly, RNA encoding the PDE7A1 regulatory domain is found in these mice while RNA encoding the catalytic domain and PDE7A catalytic activity are ablated. It remains to be determined whether expression of the PDE7A1 regulatory domain in these PDE7A-deficient mice blocks the PKA activity that results from the ablation of PDE7A catalytic activity.
Compartmentalization of PKA and phosphodiesterases is integral to cAMP signal transduction. Localization of PKA to multiple subcellular sites via interactions of its regulatory subunit with anchor proteins is required for efficient transmission of cAMP signals (reviewed in Refs. 8, 9, and 50). The presence of different PDE4D splice variants in ternary complexes with PKA, anchor proteins and other signaling molecules in the vicinity of the ␤-adrenergic receptor have been demonstrated to play a role in the activation of ERK (51, 52) . Ternary complexes in the vicinity of perinuclear membranes of cardiomyocytes assemble a negative feedback loop containing three cAMP targets: PDE4D3, PKA, and Epac (53, 54) . The localization of PKA II to the outer surface of the Golgi via AKAP85 and MTG, and to the centrosome via AKAP450 has been documented (53, 55, 56) as has been an association between PDE7A1 and PDE4A with MTG (57) . In pancreatic ␤-cells, where PDE7A1 and PKA II are co-localized, potentiation of glucose induced insulin secretion by cAMP requires the localization of PKA to specific sites within the cell (58) . It remains to be determined whether the association of PDE7A1 with PKA II and the Golgi plays a role in the regulation of responsiveness of pancreatic ␤-cells to glucose.
PKA II and PKI are ubiquitous proteins and the role of PKI in nuclear export of C provides a mechanism for terminating nuclear cAMP signaling during interphase. Low level PDE7A1 expression is detectable in many tissues and its expression levels are higher in fetal tissues (32) . It is therefore possible that catalytic and non-catalytic functions of PDE7A1 contribute to the termination of PKA signals in many fetal tissues and potentially also in some adult tissues. PDE7A1 can contribute both to the control of basal cAMP and PKA II activity levels and to termination of cAMP signals in the vicinity of the Golgi and the centrosome. Noncatalytic inhibition of PKA activity by PDE7A1 may therefore be evident only in cells/tissues where basal cAMP and PKA activity levels are of physiological relevance, and/or where selective inhibition of a subset of cellular PKA is required.
Divergent N-terminal regulatory regions of cyclic nucleotide PDEs contain distinct domains that confer multiple modes of regulation of PDE activity via allosteric cyclic nucleotide binding sites, phosphorylation sites, Ca ϩ2 /calmodulin binding sites, inhibitory proteins binding sites and auto-inhibitory domains (25, 26) . In addition, regulatory domains contain targeting sequences that localize PDEs to distinct subcellular sites (59 -61) . The N terminus of PDE7A1 possesses a novel property in its ability to inhibit enzymatic activity of PKA, while its PDE activity is not affected by the interaction with PKA. Sequences of PKA pseudosubstrate sites have not been found in the regulatory domains of cyclic nucleotide PDEs whose sequences are present in the human genome and in current databases. Thus, among cyclic nucleotide PDEs, inhibition of C is unique to PDE7A1.
